Abstract: The aim of this study was to characterize the clinical signs and symptoms of exposures to aripiprazole overdoses. We retrospectively identified all aripiprazole exposures reported to the Danish Poison Information Centre (DPIC) from June 2007 to May 2015. Information concerning demographics, ingested dose and symptoms was extracted from the DPIC database and medical records. Information on death and admission to hospital was obtained from Danish national registers. We analysed 239 cases, 86 concerning single-drug exposures to aripiprazole, and 153 cases where aripiprazole had been taken with at least one other substance (mixed-drug). The median ingested aripiprazole dose was 105 mg (IQR: 50-1680 mg) in the single-drug exposure group and 120 mg (IQR: 60-225 mg) in the mixed-drug exposure group. The most commonly reported symptom was light sedation, reported in 63% of the single-drug group and 50% of the mixed-drug exposure group. There were no malignant arrhythmias or ECG abnormalities after single-drug exposures. No deaths were recorded in relation to the intake. We found a long-term mortality rate of 13 deaths per 1000 person-years (95% CI: 7; 23 per 1000 person-years), which is significantly higher than in an age-and gender-matched background population. In conclusion, we found that aripiprazole overdoses had few and mild symptoms predominantly related to the sedative properties. We detected a benign cardiovascular safety profile and no new safety concerns. Our findings may support an increased threshold of 300 mg for hospital admission after a single-drug exposure with aripiprazole and symptoms not worse than light sedation.
Aripiprazole is a second-generation antipsychotic drug [1] . It was approved by the U.S. Food and Drug Administration in 2002 and by the European Medicines Agency in 2004 for treatment of adult schizophrenia and bipolar disorder. Aripiprazole acts as a partial agonist at the dopamine D 2 and serotonin 5-HT 1A receptors and as an antagonist at serotonin 5-HT 2A receptors. The combined dopamine and serotonin activity results in an improvement of symptoms of schizophrenia and in a low rate of extrapyramidal symptoms (EPS) [1] . Aripiprazole is generally well tolerated in comparison with other second-generation antipsychotics, and it seems to have fewer harmful effects in overdose [2] [3] [4] . Despite the fact that aripiprazole was the most prescribed antipsychotic drug in the United States in 2014 and the fifth most prescribed antipsychotic drug in Denmark, there is only limited literature on aripiprazole exposure and overdose [5, 6] .
The objective of this study was to investigate the clinical signs and symptoms of acute aripiprazole exposures and poisonings reported to the Danish Poison Information Centre (DPIC) and to assess the short-term and long-term outcome, as evaluated by readmission to hospital or death.
Methods
This retrospective study used data from the DPIC database. The DPIC is the national poison information centre for approximately 6 million people living in Denmark, Greenland and the Faroe Islands. The DPIC provides 24-hr assistance to both the general public and healthcare professionals with the management of acute poisonings. The centre collects information on all calls using the same specifically designed database to ensure consistency. Telephone calls to the DPIC are answered by nurses trained in clinical toxicology. If necessary, backup is provided by physicians specialized in anaesthesiology, occupational medicine or clinical pharmacology, and by pharmacists. The physicians and pharmacists maintain and update guidelines on specific poisonings. All reports to the DPIC from June 2007 to May 2015 concerning aripiprazole were identified and extracted from the database. Acute exposures were defined as an overdose of aripiprazole taken within a 24-hr period.
The extracted data included patient demographics (age and sex), reason for exposure, exposure site, ingested dose, co-ingestants and clinical symptoms and parameters (somnolence, nausea, vomiting, heart rate, tremor, dystonia, agitation, dizziness, paraesthesia, pupil reaction, abnormal electrocardiogram (ECG), blood pressure and respiratory failure requiring intubation) reported at the time of contact to the DPIC. Cases with incomplete (e.g. lack of important information on age or dose) or incorrectly registered data were excluded together with chronic exposures. Cases concerning adults (age above 13 years) where the estimated dose was within the recommended therapeutic range (≤30 mg) were also excluded. There is no indication for aripiprazole administration in individuals under 13 years of age. Therefore, all children were included, no matter the dose ingested. Enquiries concerning the same incident were merged into a single case. To complete data, copies of medical records were, if present, obtained from the hospitals to which the patients had been admitted. Data from the DPIC database and medical records were used to describe demographics, exposure and vital signs. In addition, we investigated whether there was any correlation between the ingested aripiprazole dose and symptoms. Symptoms were evaluated from DPIC data and medical records. Sedation was categorized as follows: (i) no sedation if the Author for correspondence: Amalie P. Christensen, Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, Bispebjerg Bakke 23, 2400 Copenhagen NV (e-mail malle_pc@hotmail.com). patient was described as awake and relevant; (ii) light sedation if sleepy, but easily awoken by verbal stimuli; (iii) moderate sedation if the patient could only be awakened by physical stimuli; or (iv) severe sedation if the patient was not able to be awakened at all. If no categorization of heart rate had been made in the DPIC database or medical record, adult patients with a heart rate above 110 beats per minute (bpm) or below 40 bpm were registered as having tachycardia or bradycardia, respectively. All other symptoms and clinical signs (such as dystonia, tremor, agitation, dizziness, paraesthesia, pupil reaction, syncope, nausea and emesis) were registered if they were described specifically in the DPIC data sheet or the medical records.
Information concerning death and readmission to hospitals with a diagnosis of drug poisoning (International Classification of Diseases 10th Danish revision (ICD-10) codes T36 to T50, T65.9, F10.0 to F19.0 and X60 to X65) was obtained from the Danish National Hospital Registry and Cause of Death Register in the same period. The relevant cases in the DPIC database were linked to the Danish National Hospital Registry and the Cause of Death Register using a unique personal identification number given to all Danish residents at birth or upon immigration. The Danish National Hospital Registry contains information about admission data and discharge diagnosis classified according to ICD-10 [7] . The Cause of Death Register records the causes and dates of all deaths in Denmark [8] . Information about cause of death including underlying causes and contributory causes and date of death was obtained from the Cause of Death Register. Information about admission department, referral diagnosis, action diagnosis, other diagnoses, date and time of hospital admission and discharge, treatments, examinations and procedures was obtained from the Danish National Hospital Registry. Hospitalization or death occurring within 30 days of the acute poisoning was defined as a short-term event and was further investigated through medical records. Readmission and death occurring after 30 days of the poisoning was defined as long-term follow-up and was not investigated individually.
Statistics. Statistical analyses were performed using R (version 3.2.3) [9] . Continuous variables were reported as median and interquartile range (IQR). Logistic regression was used to assess correlation between dose and symptoms and co-ingestants and symptoms. Timeto-event (death or readmission) curves were calculated with the use of the Kaplan-Meier method. The expected mortality rate was calculated from the age-and gender-specific mortality rates from 2013 to 2014 obtained from StatBank Denmark [10] . 
Results
Between June 2007 and May 2015, a total of 450 cases of aripiprazole overdoses were identified in the DPIC database. Two hundred and eleven cases were excluded, leaving 239 enquiries for analysis ( fig. 1 ). Medical records were obtained from 129 cases. Demographic data and exposures are presented in table 1. Of the analysed cases, 86 (36%) of the patients had only ingested aripiprazole (single-drug exposure), leaving 153 patients who had ingested at least one other drug along with aripiprazole (mixed-drug exposure). The main reason for exposure was attempted suicide (73%, n = 175 cases). In the mixed-drug exposure group, attempted suicide was reported in 83% (n = 127) of the cases compared to 56% (n = 58) of the single-drug exposure cases. In the single-drug exposure group, the second-most prevalent exposure reason was therapeutic error. Children's play/exploration as a reason for exposure constituted 9.3% (n = 8) in the single-drug exposure group compared to 0.7% (n = 1) in the mixed-drug exposure group. This is in line with the notion that the age group 0-6 years constituted a larger proportion of the cases in the single-drug exposure group. The most common drug to be ingested together with aripiprazole was another antipsychotic (n = 78, 51%) followed by antidepressants (n = 72, 47%), antiepileptics excluding clonazepam (n = 32, 21%), benzodiazepines (n = 37, 24%), zolpidem or zopiclone (n = 15, 15%) and paracetamol (n = 21, 14%). Alcohol was ingested in 12 (8%) of the cases. The median ingested dose of aripiprazole was 105 mg (IQR: 50-1680 mg) in the single-drug exposure group and 120 mg (IQR: 60-225 mg) in the mixed-drug exposure group.
Symptoms were present in 48% in the single-drug exposure group and 74% in the mixed-drug exposure group. We found no correlation between the ingested dose and the presence of symptoms ( fig. 2) , even when adjusted for intake of other drugs (odds ratio 1.12/100 mg aripiprazole, 95% confidence interval (CI): 0.998; 1.29). The most prevalent symptom was light sedation in both the single-and mixed-drug exposure group, which occurred in 31% and 45% of the cases, respectively (table 2) . Concomitant intake of zolpidem or zopiclone (OR: 16.7, 95% CI: 3.3-306), high-dose first-generation antipsychotics (OR: 2.8, 95% CI: 1.3-6.5) and quetiapine (OR: 4.2, 95% CI: 1.3-18.8) were significantly associated with an increased risk of sedation. The second-most prevalent clinical sign was tachycardia, which was observed in 15% of the patients in the single-drug exposure group and in 35% of the patients in mixed-drug exposure group. Only quetiapine was significantly associated with an increased risk of tachycardia (OR: 5.6, 95% CI: 1.8-19.0). Clinical features associated with EPS such as tremor and dystonia were reported in three cases in the single-drug exposure group. Cardiovascular effects (abnormal heart rate, ECG and blood pressure) were more prevalent in the mixed-drug exposure group than in the single-drug exposure group, and ECG abnormalities (primarily QT prolongation) were only reported in the mixed-drug exposure group, mainly with antiepileptics (OR: 5.8, 95% CI: 1.4-23.1). In the single-drug exposure group, none of the cases required vasopressors or admission to the ICU. Within the first 30 days after the aripiprazole overdose, there was one recorded death not directly related to the overdose (bacterial pneumonia diagnosed after discharge from the hospital). Of the 197 persons identified in the National Patient Registry, there were 10 deaths during 922 person-years of follow-up with a median follow-up time of 4.6 years from the first enquiry to the DPIC regarding aripiprazole. This corresponds to a mortality rate of 10.8 deaths per 1000 personyears (95% CI: 4.3; 18.4 per 1000 person-years). This mortality rate is significantly increased compared to an age-and gender-matched background population, where it is 0.72 per 1000 person-years. Of the 10 deaths, five were due to suicide (one from an unknown drug, one with tricyclic antidepressant, two by hanging and one by drowning), one died from alcohol abuse, one from a femur neck fracture, one from pneumonia, one from stroke and the remaining patient died from methadone overdose. We found that within the first year of the aripiprazole exposure, almost half of the cases were readmitted to a hospital with a new diagnosis of drug poisoning ( fig. 3) .
Discussion
This study is based on 239 cases of aripiprazole exposure with data from the DPIC, patient medical records and Danish National Hospital Registry. We found that ingestion of aripiprazole in overdose was generally well tolerated and caused no short-term fatalities. The most prevalent symptom was light somnolence. This is in line with previously reported cases and studies [11] [12] [13] [14] [15] [16] [17] . A possible explanation for this could be the antagonistic effect of aripiprazole on the histamine H 1 receptor. Aripiprazole has moderate affinity for the receptor (K i value of 61 nM) and limited sedating effect with therapeutic doses, but accentuation of this receptor interaction may explain the sedation seen in overdoses. Our study revealed no severe cardiotoxicity in the single-drug exposure group, which is consistent with previous studies concerning overdose with aripiprazole [3] . Polcwiartek et al. found that aripiprazole had a safe cardiac profile [18] , and an updated search of the literature revealed no reports of severe cardiotoxicity. Among the single-drug exposures, the prevalence of EPS was minimal. The reason for this may be found in the receptor profiles, as aripiprazole only shows partial agonist activity at the D 2 receptor and antagonist activity at the serotonin 5-HT 2A receptor [19, 20] . There has been one report of persisting lethargy and intention tremor in a two-year-old patient after reported ingestion of 10 mg of aripiprazole [21] . The authors suggested that the patient might have been a poor metabolizer of cytochrome P450 2D6 (CYP2D6), which, along with CYP3A4, is the main metabolizing enzyme of aripiprazole. This was not confirmed with any genetic testing. In our cases involving 0-to 6-year-old children (12 single-drug aripiprazole exposures), none experienced tremor or dystonia. Light somnolence was the main symptom in the youngest age group (4/12 cases), which is consistent with the previous literature [22] .
Even though there was a positive correlation between the ingested dose and the occurrence of symptoms, it was not statistically significant. This might be due to a limited number of cases with high aripiprazole ingestion ( fig. 2) or early treatment of the overdose reducing the occurrence of symptoms. Likewise, the uncertainty in the intake may also hide a potential dose response. Ingestion and reporting of correct doses of aripiprazole was not confirmed by measurements of plasma concentrations, and the obtained doses were solely based on reports from the patients or involved caretakers. However, correlation between doses reported by patients and laboratory results has previously been shown to be a reliable measure in pharmacokinetic studies concerning populations of overdose patients [23, 24] . As mentioned, none of the reported cases were lethal. Nevertheless, we found a significantly increased long-term mortality among the reported cases when compared to an age-and gender-matched background population. The reason for the increased mortality is most likely due to an increased occurrence of psychiatric illness, suicide and abuse among the cases. This is in agreement with previous studies which have also demonstrated an increased risk of subsequent suicide after admission to a hospital with a diagnosis of drug poisoning [25, 26] . A new poisoning leading to hospitalization within the first 6 months after the reported overdose with aripiprazole was observed in half of the cases. The incidence of readmission to the hospital due to self-poisoning after prior hospitalization caused by atypical antipsychotic overdoses has not been reported earlier. Other studies have, however, found that previous admission for self-harm (within 12 months) is the strongest predictor for a new admission due to self-harm in a psychiatric population [27, 28] . Somatic admission due to poisoning may be considered a marker of treatment success/failure in this patient population.
There were some limitations to this study. The retrospective method of data review inevitably leads to insufficient collection of data. Additionally, as data from the DPIC are obtained over the phone, we were only provided with information about the patients' conditions up to the time of the contact with the DPIC; vital parameters and symptoms are often incompletely reported or may not be present. Furthermore, cases presenting without symptoms may not be reported to the DPIC. Therefore, reported clinical patterns might not be representative of all aripiprazole exposures. We were only able to obtain medical records for 54% of the cases. For these cases, the quality of data was improved; particularly, symptoms were more elaborately described here than the cases where we failed to supplement the DPIC data. This could be of concern if the obtained medical records were not equally distributed between single and mixed exposure and low and high doses. However, we did not find any indication of this being the case.
In conclusion, we found that an overdose of aripiprazole has few and mild symptoms predominantly related to the sedative properties. Our data support the notion of a benign cardiovascular safety profile of aripiprazole also in overdoses and reveal no new safety concerns for this commonly used antipsychotic. These findings support an increased threshold for somatic admission of single-drug exposures with aripiprazole in DPIC guidelines to 300 mg if there are no symptoms besides light sedation. A B Fig. 3 . Kaplan-Meier curves of the mortality probability (A) and readmission probability (B) in relation to time. Curves are provided with 95% confidence intervals.
